One key team member that was brought on board is David Markus (Vice President, BioMEMS) Developer, As you will see David Markus is a Well Accomplished Engineer. David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. Dr. Markus spent 11 years with Raytheon and holds 8 US patents and has 9 other US Patents Pending. He has been involved in research for several of the world's leading technological institutions, including the Office of Naval Research in Arlington, Virginia, NASA Jet Propulsion Laboratory in Pasadena, CA and he has been published 15 times for various technical conferences. He was a principal investigator on SBIR DARPA Phase I and Phase II, and "Ultraflexible Substrate" for Macroelectronics Program by Dr. Robert Reuss at DARPA. He has been involved in the engineering and the development on seven surgical devices, including devices for Cataract surgery, Intra-Ocular Lens Delivery, Arthroscopy, Endodontic Endoscope, Micro Endoscope and Neural Electrodes. Additionally he was instrumental on developing three medical laboratory devices, including for In-Vitro Fertilization, PCR instrumentation and drug discovery. The Company claims to have significant know-how and Intellectual Property in the arena of BioMEMS and claims to have invented new device technologies which include, but are not limited to the following:
People, Products & Process:
EPGL has assembled an impressive team to propel the company into a bright future and to build shareholder value. Under the leadership of Michael Hayes EPGL underwent debt restructuring, assembly of a new management team, as well as medical and scientific personnel. Mr. Hayes has made it a singular priority to bring aboard only the world’s top professionals in the field of medical sciences to EPGL and thereby build the Company into a major player in the Medical Device Industry over the next several years. He has also committed to prioritizing shareholders and creating significant value for their investment over time. We have seen great evidence of the har work over the last couple years as EPGL has signed Development Agreements with CooperVision, Intel, and AT&T. EPGL is in negotiations to licence technology to CooperVision presently. On April 28th 2015, EPGL disclosed to shareholders that EPGL and AT&T have created joint Intellectual Properties and are now in the process of procuring those properties. Shareholders can expect developments on this in the near future.
|1. Advanced Power Source for Contact Lenses ||11. Advanced TopSpin Platform Technology for Development of Smart Medical Devices |
|2. Advanced Cell Regeneration Technology to Treat Eye Disease ||12. Advanced Device for Steam Cell Treatment Delivery |
|3. Advanced Cell Regeneration Technology to Treat Hearing Loss ||13. Advanced Device for Treatment of Prostate Tumors |
|4. Advanced Nerve Ablation Device ||14. Advanced Endoscopic Device |
|5. Advanced Epidural Device ||15. Advanced Device for Delievery of Micron Sized Drug Payloads |
|6. New & Promsing Treatment of Restinitis Pigmentosa ||16. New & Promising Device for Treatment of Macular Degeneration |
|7. Advanced Ablation Device for Nerve Treatment of Facial Glabballar Frownig ||17. New Advanced Contact Lens Device |
|8. New Advanced PowerSource for TopSpin Medical Devices ||18. Advanced Device For Delivery of Micro Mechanical Devices Into Body |
|9. Advanced Trigger Point Needle Device ||19. Device for Advanced Biopsy |
|10. Advanced Micron Resolution Motor for Smart Medical Devices ||20. Real-Time Sensor Technologies for Connectivity to a Global Network **NEW |
21.Real-Time Data Applications for Athletic Teams, Workforces and Military Forces*NEW
About EPGL Medical Science's Share Structure :
EPGL has a share structure of 5 billion authorized shares with approximately 4.5 billion shares restricted and a float of approximately 499 million. Following a very successful Reverse Split EPGL has decreased the float by 90% and increased share holder value by over 500% since that time. The company has strongly stated many times that they will not sell shares into the retail market. They are here to build a real company and implement real growth. Since restructuring EPGL has not increased the Float/OS/AS and have given us there word on countless occasions they will not do so.
Pricewaterhouse Coopers, Corporate Finance and Recovery (Cayman) Ltd.Controlling Agent for:
AJW Qualified Partners, LLC, Controlled by PwC (PricewaterhouseCoopers) - Court appointed
1.975 Billion Common Shares
Mr. Michael Hayes
1.975 Billion Common Shares
FLOAT/TRADABLE SHARES : 499 Million ***Unchanged since Restructure in 2012***
Total number of shareholders of record 700 approximate
The Company claims to have leases or utilizes facilities in the following locations
Various California Bay Area Research Facilities Under NDA, David T. Markus, Ph.D.
Irvine, California – Research Facilities, Office
New York University Langone Medical Center, Corey W. Hunter M.D. / Eric Lee M.D.
University of Minnesota, David T. Markus, Ph.D.
University of California at Irvine, David T. Markus, Ph.D.
Dallas and Plano Texas, David T. Markus, Ph.D. **NEW**
Follow EPGL on the WEB at http://www.epglmed.com